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Introduction
The aim of this study was to determine the influence of neoadjuvant chemotherapy, NACT, on the immune microenvironment in peritoneal metastases of high-grade serous ovarian cancer, HGSC. Early peritoneal and pleural spread is a feature of HGSC with a majority of patients presenting with FIGO stage IIIC and stage IV disease (1).
Platinum-based chemotherapy is the only backbone medical first line treatment approved for HGSC in the past thirty years and although most patients respond initially, resistance eventually develops in a majority of them. Peritoneal metastases are frequently the site of relapse and eventually lead to bowel obstruction that contributes to death in many patients (2, 3) .
In patients with Stage IIIC or IV disease who are not suitable for primary debulking surgery (PDS), three cycles of platinum-based NACT followed by interval debulking surgery (IDS) and adjuvant chemotherapy is an accepted alternative approach. This is equally effective while potentially associated with lower morbidity (4, 5) although there is a need for international consensus criteria for patient selection in this approach.
There is good evidence that HGSC has potential to be an immunogenic tumor and activated T cells have been characterized in the tumor microenvironment and ascitic fluid (6) (7). There is an association between increased tumor-infiltrating leukocyte, TIL, density and longer survival (8, 9) and TIL sub populations recognize shared tumor antigens, gene products from somatic mutations, as well as amplified or aberrant genes (10, 11) . Mutation frequency also correlated with an immune cell cytolytic activity transcriptional signature in ovarian cancer databases (12) . However, TIL in HGSC biopsies are often suppressed or functionally exhausted, and immunotherapies, until recently, not yet had a major impact on patients with advanced chemo-resistant disease (10, 11, 13) .
Recent studies in animal cancer models have shown how the immune system plays an important role in the response to some cancer chemotherapies, inducing an 'immunogenic' cell death, presentation of neoantigens and an increase in acute inflammatory and tumor-destructive responses (14) (15) (16) . Furthermore, recent mouse cancer experiments showed the efficacy of blocking the PD-1/PD-L1 axis following paclitaxel chemotherapy (17) . The ability to sample HGSC biopsies at diagnosis and after NACT during surgery, gives us an opportunity to ask if similar responses occur in a clinical setting and if they do, whether this provides a rationale for introducing immunotherapy after NACT rather than in relapsed disease. We therefore studied a cohort of fifty-four women with stage IIIC and stage IV HGSC receiving NACT, as well as six women who underwent surgery before chemotherapy. Using transcriptional and protein analyses of prospectively collected metastatic peritoneal (omental) specimens, as well as plasma samples, we investigated the effects of platinum-based NACT on the immune microenvironment in patients and compared this to their response to chemotherapy as assessed by a recently published prognostic histologic score (18) .
Materials and Methods

Patients and samples
Institutional review board approval was granted for the Barts Gynae Tissue Bank to collect and store biological material and clinical information. Patients were treated at St Bartholomew's Cancer Centre between 2010 and 2015 and gave written informed consent. Clinical parameters were collected using tissue repository databases and chart review.
Omental metastases and plasma samples from fifty-four FIGO stage IIIC and IV HGSC patients were collected prospectively before and after platinum-based neoadjuvant chemotherapy (details of patients and treatment are shown in Supplementary Table 1) and analysed in immunohistochemical, flow cytometric and transcriptomic experiments.
Surgery was usually performed between three and four weeks after the last NACT.
Samples from an additional six patients with FIGO stage IIIC and IV HGSC who underwent primary debulking surgery were used in the flow cytometry and RNAseq studies described below (Supplementary Table 2 ). These samples were matched to the NACT cohort in terms of amount of tumor and stroma in the biopsy, pre-treatment levels of plasma cytokines, age and stage. Inflammatory cytokine levels were measured in paired pre and post NACT plasma samples of twenty-three patients and twenty-two plasma samples were from healthy female volunteers (median age 47.5y, range 32 -64). Supplementary Table 3 lists the numbers of samples that were used in each of the analyses.
The response to chemotherapy was assessed in IDS biopsies using a chemotherapy response score (CRS) that separates the patients into three major subgroups (18) . CRS1 samples show minimal response to chemotherapy, CRS2,'poor' responders, have easily identifiable malignant cells in the omentum after NACT and CRS3, 'good' responders, usually show extensive regression-associated fibro-inflammatory changes with absent or minimal numbers of malignant cells (18) .
Formalin-fixed paraffin embedded (FFPE) tumor biopsies
Pre-treatment omental or peritoneal biopsies were obtained at diagnostic laparoscopy or diagnostic core biopsy. Sections of 4µm thickness were mounted on glass slides.
Blocks of omentum removed at interval debulking surgery after neoadjuvant chemotherapy, were reviewed by a pathologist according to ICCR guidelines (19) .
Blocks representing the area of worst response were selected and used to construct tissue microarrays (TMA) with a 1mm core size and up to 6 cores per patient sample.
Fresh tumor biopsies
Omental biopsies were collected in the operating theatre from untreated patients undergoing primary debulking surgery, PDS or diagnostic laparoscopy and from patients undergoing interval debulking surgery after NACT and fresh-frozen samples were histologically matched to FFPE specimens of the same patient by H&E review.
Blood samples
Sodium heparin blood (BD Vacutainer Systems) was immediately placed on ice within one week before NACT and within two weeks before IDS. The minimum time after the last cycle of chemotherapy was three weeks. Following centrifugation plasma from patients and controls was snap frozen and stored at -80°C.
Extraction of stroma vascular fraction
Fresh omental biopsies were subjected to mechanical dissection and enzymatic treatment. Briefly, the tissue was dissected with a scalpel, incubated in RPMI medium (Gibco) containing 5% FBS, 1mg/ml Collagenase D from clostridium histolyticum (Roche) and 25µg/ml DNAse (Roche) at 37°C under agitation for 40min. The extract was then filtered through a 70µm pore strainer; red blood cells were lysed (eBioscience) and the Stroma Vascular Fraction (SVF) was frozen for later FACS analyses or freshly re-stimulated in vitro for intra-cellular cytokine staining.
Flow cytometry analyses
SVFs and peripheral blood mononuclear cells (PBMCs) were stained for flow cytometry analyses in PBS containing 2.5% BSA and 2mM EDTA for 30min at 4˚C. The following markers were used: CD45 APC efluor780 (eBioscience), CD3 BV650 (Biolegend), CD3 PE (eBioscience), CD4 PerCP-Cy5. 5 
Immune cell quantification on digitalized slides
Immunohistochemically stained slides were scanned at 20x with a Pannoramic Flash 
Scoring of PD-L1 expression
PD-L1 was scored by a study pathologist using the criteria described in (20) . Briefly, samples were scored for PD-L1 expression on tumor-infiltrating immune cells, which included macrophages, dendritic cells and lymphocytes. Specimens were given a score of 0-3 if <1%, 1-<5%, 5-<10% and ≥10% of cells were positive for PD-L1.
Plasma cytokine analysis
Cytokines were measured by electrochemiluminescence multiplex assay (V-Plex, MSD) on a Sector Imager (MSD) according to the manufacturers' protocol. The detection range for the assays was as follows: TNFα: 0.076pg/ml to 311 pg/ml; IL8: 0.133 pg/ml to 546pg/ml; IL6: 0.369pg/ml to 749pg/ml; IFNγ: 0.369pg/ml to 1510pg/ml; IL10:
0.076pg/ml to 313pg/ml; IL17: 1.38pg/ml to 5670pg/ml.
RNA isolation
Total RNA was isolated from frozen whole tissue using the RNeasy kit (Qiagen)
following the manufacturers' instructions. Briefly, whole tissue was homogenized in RLT lysis buffer, passed through a QIAshredder (Qiagen) then purified on the mini spin columns, including the on-column DNAse treatment to remove any remaining DNA. The purified total RNA was then analyzed by Bioanalyzer 2100 expert (Agilent) as per manufacturers' instructions. RIN numbers between 9.9 and 8.0 were obtained. 
Transcriptomic analysis
Data and materials availability
FASTQ data files supporting the RNASeq analysis have been uploaded to NCBI GEO database GSE71340. Progression-free survival (PFS) was calculated from the date of first neoadjuvant chemotherapy to progression or death (whichever came first) using GCIG CA-125 criteria for biochemical progression. Overall survival (OS) was calculated from the date of first neoadjuvant chemotherapy to death from HGSC. Survival functions were estimated using the Kaplan-Meier method and the log-rank test was applied.
Statistical analysis
Results
Response to chemotherapy in the study cohort
Samples from a total of fifty-four patients receiving NACT and six patients who had surgery prior to chemotherapy were used in the experiments in this paper.
Supplementary Table 3 summarizes the sample numbers used in each set of experiments. As described above, the response to chemotherapy was assessed in the interval debulking, IDS, biopsies using the CRS (18) . CRS1 samples show minimal response to chemotherapy, CRS2,'poor' responders, have easily identifiable malignant cells in the omentum after NACT and CRS3, 'good' responders, usually show extensive regression-associated fibro-inflammatory changes with absent or minimal numbers of malignant cells (18) . None of the IDS samples in our experiments, by chance and due to prevalence, scored as CRS1. 'Good responder' patients with samples scored as CRS3
had significantly improved progression-free survival (p=0.002) and overall survival (p=0.03) compared to 'poor responder' patients whose biopsies scored as CRS2
(Supplementary Figure 1) .
T cell density pre and post NACT
From twenty-five of the HGSC patients described above, we obtained matched omental biopsies taken at pretreatment and at IDS. Using immunohistochemistry, the biopsies were stained for CD8 + T cells, CD45RO + memory cells and Foxp3 + T regulatory cells. Figure 3) .
In contrast, there was a significant decline in the density of Foxp3 + cells in the stromal areas of the CRS3 'good' responder biopsies after NACT (p=0.02) but there was no significant change in the CRS2 biopsies ( Figure 1 ). As Foxp3 is a marker of immunosuppressive T regulatory cells, we next asked whether NACT increased T cell activation.
Evidence for T cell activation after NACT
We assessed the phenotype of the T cells in the HGSC omental metastases by flow cytometry analysis of tumor-infiltrating leukocytes from twenty-two of the HGSC biopsies. As it was not possible to obtain sufficient material for flow cytometry from diagnostic biopsies for pretreatment samples in these experiments, to assess pretreatment T cell phenotypes we used six samples obtained at primary debulking and two laparoscopic biopsies obtained before NACT. In agreement with the results in 
Gene set enrichment analysis of immune gene signatures pre and post NACT
We extracted total RNA from twenty of the HGSC omental metastasis biopsies for which we had sufficient material and analysed gene expression by RNAseq. Nine samples were from CRS3 good responders post NACT and seven from CRS2 poor responders.
For pre-treatment samples we used two biopsies from stage IIIC or IV HGSC patients undergoing primary debulking surgery and two biopsies obtained from patients before NACT as described for Figure 2 . Gene set enrichment analysis (GSEA) was conducted
Changes to immune cell phenotypes from both the adaptive and innate pathways were seen when comparing CRS3 to CRS2 samples, and individually (CRS2 or CRS3) to Pre NACT samples. In particular changes associated with T-cell phenotype were found to have the highest significance (lowest FDR value). In agreement with the results in Figures 1 and 2 , we found that the FOXP3-associated T regulatory cell gene signatures were differentially regulated in pre versus post NACT patients. FOXP3 regulated genes whose expression is decreased following differentiation to a T regulatory phenotype (25) were enriched in pretreatment versus both CRS2 and CRS3 post NACT biopsies ( Figure 3A and B). We also observed an enrichment of this gene signature in CRS2
poor responder biopsies compared to CRS3 biopsies ( Figure 3C ).
Further GSEA analysis revealed an increase in expression of T-helper 1 (Th1)-associated genes after NACT in both poor (CRS2) and good (CRS3) responders ( Figure 4A , 4B). The gene set used contained genes that were experimentally upregulated when naïve T-cells were activated to a Th1 phenotype in vitro (26) . We also noted that the Th1 phenotype was enriched in CRS3 patients compared to CRS2
( Figure 4C ). Meta analysis of TCGA data has identified GZMA (encoding granzyme A) and PRF1 (encoding perforin 1) as specifically co-expressed by cytotoxic T-cells (12) .
We compared gene expression levels for both markers within our data set ( Figure 4D-F ). There was a tendency for both genes to be upregulated in the post NACT versus pretreatment samples and the difference with PRF1 was significant p=0.03 ( Figure   4D ,E). The geometric mean of both genes ( Figure 4F ) again showed a tendency towards upregulation post-NACT. These experiments suggest that NACT reduced T regulatory cell activity in HGSC metastases while increasing T cell activation and Th1 responses and these effects were most profound in the CRS3 good responder patients.
We next asked if the potential for efficient host anti-tumor immune responses was influenced by immune checkpoint molecules.
The effect of NACT on immune checkpoint molecules
More than 60% of CD4 + and CD8 + T cells in omental metastases from six pre and sixteen post NACT patients expressed the immune checkpoint molecule programmed cell death-1 (PD-1) as assessed by flow cytometry (Figure 5A 
Plasma levels of cytokines
Cancer-related inflammatory pathways can also contribute to the immune suppressive tumor microenvironment (27) and ovarian cancers have complex tumor-promoting inflammatory cytokine networks (28) that can be reflected by increases in systemic cytokine levels (29) . We measured key cytokines implicated in tumor-promoting inflammation, as well as T cell activation and immune suppression, in forty-six matched pre and post NACT plasma samples from twenty-three patients. Levels of three major inflammatory cytokines with potential tumor-promoting activity, TNF, IL-8 and IL-6, significantly decreased after NACT (p=0.0008, p=0.001 and p=0.0006, respectively, Figure 6A -C). All plasma levels were elevated pre-treatment but post NACT levels were not statistically different from values obtained from twenty-two healthy females. There were no differences between patients whose samples were scored CRS2 and CRS3.
In contrast, plasma IFNγ was increased in post treatment patients compared to healthy controls (p=0.005) with a trend towards an increase post-treatment versus pre-treatment ( Figure 6D ). Pre-treatment patient plasma IL-10 levels were significantly higher compared to controls before NACT (p=0.04) and decreased after NACT (p<0.001
( Figure 6E ). IL-17 levels were significantly elevated in HGSC patients compared to controls (p=0.006) and remained elevated after NACT (p=0.02, Figure 6F ). There is much evidence that cancer-related inflammation is also tumor-promoting (44) although clinical trials that target inflammatory mediators or cells are not as advanced as some other immunotherapy approaches (27) (34) . As the adaptive immune response is heavily dependent on innate immunity, inhibiting some of the tumor-promoting immunosuppressive actions of the innate immune system might enhance the potential of immunotherapies that activate a nascent antitumor response. It is therefore encouraging that NACT had a significant impact on systemic levels of three key inflammatory cytokines in our study. TNF and IL-6 are major players in the complex cytokine networks that drive tumor progression in ovarian cancer (28, 29, 45) . Elevated 
Discussion
